SEC Comment Letter for Monopar Therapeutics (MNPR) (CIK 0001645469) (MNPR) — Jan 9, 2018

Monopar Therapeutics (MNPR) (CIK 0001645469)
Date: Jan. 9, 2018 · CIK: 0001645469 · Accession: 0000000000-18-000858

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

January 8, 2018

Author

Chandler D. Robinson

Form

UPLOAD

Company

Monopar Therapeutics (MNPR) (CIK 0001645469)

Letter

January 8, 2018 Chandler D. Robinson Chief Executive Officer Monopar Therapeutics Inc. 5 Revere Drive, Suite 200 Northbrook, Illinois 60062 Monopar Therapeutics Inc. Registration Statement on Form 10-12G Filed November 9, 2017 File No. 000-55866Re: Dear Dr. Robinson: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: Ashley Graffeo - Baker & Hostetler, LLP

Show Raw Text

January 8, 2018
Chandler D. Robinson
Chief Executive Officer
Monopar Therapeutics Inc.
5 Revere Drive, Suite 200
Northbrook, Illinois 60062
Monopar Therapeutics Inc.
Registration Statement on Form 10-12G
Filed November 9, 2017
File No. 000-55866Re:
Dear Dr. Robinson:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence by the staff.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Ashley Graffeo - Baker & Hostetler, LLP

SecProbe.io